SERIES · Foundations
The Body’s Tiny Signal System
Peptides are short chains of amino acids that carry instructions. GLP-1 is one of them, but the signal system is much bigger.
Read More: What Do Peptides Do? The Body’s Tiny Signal SystemGLP peptides shouldbe accessible.
The science, knowledge, and pricing.
Buy GLP-3
What comes after Ozempic
GLP-3 /Retatrutide
Weight loss. Metabolic and cardiovascular health. Liver function.
Target three of your body’s receptors.
GLP-1regulates appetite and insulin.
GIPsupports glucose handling.
Glucagonsignals the body to use stored energy (fat).
What the science shows.
28,7%
Average Body Weight Loss
86%
Reduction in Liver Fat
41%
Reduction in Triglycerides
In third-stage clinical trials.
The GLP Company We Wished Existed
Our Promise
At least 10% lowerprices by 2028.
A promise that goes further, the more of us there are.
What you should know.
Peptides are simple molecules: chains of amino acids. Retatrutide has been in human trials since 2019, is currently in Phase 3, and FDA approval is anticipated in 2027. Catalyst sells the research-use-only version of the compound: a legal category distinct from the branded prescription peptide Eli Lilly is bringing to market. No dosing guidance, no medical claims.
Peptides labeled for research use do not require a prescription. They sit in a separate regulatory category, so the prescription requirement does not apply. Catalyst operates within the research-use-only (RUO) framework.
“Research Use Only” (RUO) is a regulatory designation under 21 CFR 809.10(c)(2). It applies to compounds manufactured and sold for non-clinical research, separate from products intended for diagnosis, treatment, or prevention of disease.
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. The content on Science Explained, the lab reports, and the third-party COAs is education about published research, not medical guidance.
What comes after Ozempic
GLP-3 /Retatrutide
Target three of your body’s receptors.
GLP-1regulates appetite and insulin.
GIPsupports glucose handling.
Glucagonsignals the body to use stored energy (fat).
Clinical data demonstrates advancements in weight management, liver function, and cardiovascular health.
In third-stage clinical trials.
Weight loss. Metabolic and cardiovascular health. Liver function.
28,7%
Average Body Weight Loss
86%
Reduction in Liver Fat
41%
Reduction in Triglycerides
The GLP Company We Wished Existed
At least 10% lower
prices by
A promise that goes further,
the more of us there are.
What you should know.
How can you sell a peptide that’s still in clinical trials?
Peptides are simple molecules: chains of amino acids. Retatrutide has been in human trials since 2019, is currently in Phase 3, and FDA approval is anticipated in 2027. Catalyst sells the research-use-only version of the compound: a legal category distinct from the branded prescription peptide Eli Lilly is bringing to market. No dosing guidance, no medical claims.
Why are peptides available without a prescription?
Peptides labeled for research use do not require a prescription. They sit in a separate regulatory category, so the prescription requirement does not apply. Catalyst operates within the research-use-only (RUO) framework.
What does “Research Use Only” mean?
“Research Use Only” (RUO) is a regulatory designation under 21 CFR 809.10(c)(2). It applies to compounds manufactured and sold for non-clinical research, separate from products intended for diagnosis, treatment, or prevention of disease.
Is this a substitute for medical advice?
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. The content on Science Explained, the lab reports, and the third-party COAs is education about published research, not medical guidance.